Literature DB >> 25125939

Clinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case Series.

Hayan Jouni1, Khader Shameer1, Yan W Asmann2, Ribhi Hazin3, Mariza de Andrade2, Iftikhar J Kullo1.   

Abstract

Although mosaic autosomal chromosomal abnormalities are being increasingly detected as part of high-density genotyping studies, the clinical correlates are unclear. From an electronic medical record (EMR)-based genome-wide association study (GWAS) of peripheral arterial disease, log-R-ratio and B-allele-frequency data were used to identify mosaic autosomal chromosomal abnormalities including copy number variation and loss of heterozygosity. The EMRs of patients with chromosomal abnormalities and those without chromosomal abnormalities were reviewed to compare clinical characteristics. Among 3336 study participants, 0.75% (n = 25, mean age = 74.8 ± 10.7 years, 64% men) had abnormal intensity plots indicative of autosomal chromosomal abnormalities. A hematologic malignancy was present in 8 patients (32%), of whom 4 also had a solid organ malignancy while 2 patients had a solid organ malignancy only. In 50 age- and sex-matched participants without chromosomal abnormalities, there was a lower rate of hematologic malignancies (2% vs 32%, P < .001) but not solid organ malignancies (20% vs 24%, P = .69). We also report the clinical characteristics of each patient with the observed chromosomal abnormalities. Interestingly, among 5 patients with 20q deletions, 4 had a myeloproliferative disorder while all 3 men in this group had prostate cancer. In summary, in a GWAS of 3336 adults, 0.75% had autosomal chromosomal abnormalities and nearly a third of them had hematologic malignancies. A potential novel association between 20q deletions, myeloproliferative disorders, and prostate cancer was also noted.

Entities:  

Keywords:  copy number variation; genome-wide association studies; loss of heterozygosity; mosaic abnormalities; mosaic deletion; myeloproliferative disorders; prostate cancer; unipaternal disomy

Year:  2013        PMID: 25125939      PMCID: PMC4130164     

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  36 in total

1.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis.

Authors:  Steffen Durinck; Yves Moreau; Arek Kasprzyk; Sean Davis; Bart De Moor; Alvis Brazma; Wolfgang Huber
Journal:  Bioinformatics       Date:  2005-08-15       Impact factor: 6.937

Review 2.  Conventional cytogenetics in myelofibrosis: literature review and discussion.

Authors:  Kebede Hussein; Daniel L Van Dyke; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2009-01-09       Impact factor: 2.997

3.  Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families.

Authors:  S L Zheng; J Xu; S D Isaacs; K Wiley; B Chang; E R Bleecker; P C Walsh; J M Trent; D A Meyers; W B Isaacs
Journal:  Hum Genet       Date:  2001-05       Impact factor: 4.132

4.  Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network.

Authors:  David R Crosslin; Andrew McDavid; Noah Weston; Sarah C Nelson; Xiuwen Zheng; Eugene Hart; Mariza de Andrade; Iftikhar J Kullo; Catherine A McCarty; Kimberly F Doheny; Elizabeth Pugh; Abel Kho; M Geoffrey Hayes; Stephanie Pretel; Alexander Saip; Marylyn D Ritchie; Dana C Crawford; Paul K Crane; Katherine Newton; Rongling Li; Daniel B Mirel; Andrew Crenshaw; Eric B Larson; Chris S Carlson; Gail P Jarvik
Journal:  Hum Genet       Date:  2011-10-30       Impact factor: 4.132

5.  Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors.

Authors:  F K Rae; J D Hooper; D L Nicol; J A Clements
Journal:  Mol Carcinog       Date:  2001-09       Impact factor: 4.784

6.  Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies.

Authors:  Anthony J Bench; Juan Li; Brian J P Huntly; Eric Delabesse; Nasios Fourouclas; Adrienne R Hunt; Panos Deloukas; Anthony R Green
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

7.  The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies.

Authors:  Catherine A McCarty; Rex L Chisholm; Christopher G Chute; Iftikhar J Kullo; Gail P Jarvik; Eric B Larson; Rongling Li; Daniel R Masys; Marylyn D Ritchie; Dan M Roden; Jeffery P Struewing; Wendy A Wolf
Journal:  BMC Med Genomics       Date:  2011-01-26       Impact factor: 3.063

8.  Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.

Authors:  Nathalie Douet-Guilbert; Audrey Basinko; Frédéric Morel; Marie-Josée Le Bris; Valérie Ugo; Patrick Morice; Christian Berthou; Marc De Braekeleer
Journal:  Ann Hematol       Date:  2008-03-19       Impact factor: 3.673

9.  A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region.

Authors:  A J Bench; M A Aldred; S J Humphray; K M Champion; J G Gilbert; F A Asimakopoulos; P Deloukas; R Gwilliam; D R Bentley; A R Green
Journal:  Genomics       Date:  1998-05-01       Impact factor: 5.736

10.  Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.

Authors:  N Brookman-Amissah; C Duchesnes; M P Williamson; Q Wang; A Ahmed; M R Feneley; A Mackay; A Freeman; K Fenwick; M Iravani; B Weber; A Ashworth; J R Masters
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.